This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


3eot

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (09:12, 23 February 2022) (edit) (undo)
 
(7 intermediate revisions not shown.)
Line 1: Line 1:
-
[[Image:3eot.png|left|200px]]
 
-
{{STRUCTURE_3eot| PDB=3eot | SCENE= }}
+
==Crystal structure of LAC031, an engineered anti-VLA1 Fab==
 +
<StructureSection load='3eot' size='340' side='right'caption='[[3eot]], [[Resolution|resolution]] 1.90&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[3eot]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3EOT OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3EOT FirstGlance]. <br>
 +
</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1mhp|1mhp]]</div></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3eot FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3eot OCA], [https://pdbe.org/3eot PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3eot RCSB], [https://www.ebi.ac.uk/pdbsum/3eot PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3eot ProSAT]</span></td></tr>
 +
</table>
 +
== Evolutionary Conservation ==
 +
[[Image:Consurf_key_small.gif|200px|right]]
 +
Check<jmol>
 +
<jmolCheckbox>
 +
<scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/eo/3eot_consurf.spt"</scriptWhenChecked>
 +
<scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked>
 +
<text>to colour the structure by Evolutionary Conservation</text>
 +
</jmolCheckbox>
 +
</jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=3eot ConSurf].
 +
<div style="clear:both"></div>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
A design approach was taken to investigate the feasibility of replacing single complementarity determining region (CDR) antibody loops. This approach may complement simpler mutation-based strategies for rational antibody design by expanding conformation space. Enormous crystal structure diversity is available, making CDR loops logical targets for structure-based design. A detailed analysis for the L1 loop shows that each loop length takes a distinct conformation, thereby allowing control on a length scale beyond that accessible to simple mutations. The L1 loop in the anti-VLA1 antibody was replaced with the L2 loop residues longer in an attempt to add an additional hydrogen bond and fill space on the antibody-antigen interface. The designs expressed well, but failed to improve affinity. In an effort to learn more, one design was crystallized and data were collected at 1.9 A resolution. The designed L1 loop takes the qualitatively desired conformation; confirming that loop replacement by design is feasible. The crystal structure also shows that the outermost loop (residues Leu51-Ser68) is domain swapped with another monomer. Tryptophan fluorescence measurements were used to monitor unfolding as a function of temperature and indicate that the loop involved in domain swapping does not unfold below 60 degrees C. The domain-swapping is not directly responsible for the affinity loss, but is likely a side-effect of the structural instability which may contribute to affinity loss. A second round of design was successful in eliminating the dimerization through mutation of a residue (Leu51Ser) at the joint of the domain-swapped loop.
-
===Crystal structure of LAC031, an engineered anti-VLA1 Fab===
+
An antibody loop replacement design feasibility study and a loop-swapped dimer structure.,Clark LA, Boriack-Sjodin PA, Day E, Eldredge J, Fitch C, Jarpe M, Miller S, Li Y, Simon K, van Vlijmen HW Protein Eng Des Sel. 2009 Feb;22(2):93-101. Epub 2008 Dec 10. PMID:19074157<ref>PMID:19074157</ref>
-
{{ABSTRACT_PUBMED_19074157}}
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
 
+
</div>
-
==About this Structure==
+
<div class="pdbe-citations 3eot" style="background-color:#fffaf0;"></div>
-
[[3eot]] is a 2 chain structure of [[Antibody]] with sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3EOT OCA].
+
==See Also==
==See Also==
-
*[[Antibody|Antibody]]
+
*[[Antibody 3D structures|Antibody 3D structures]]
-
 
+
*[[Sandbox 20009|Sandbox 20009]]
-
==Reference==
+
*[[3D structures of non-human antibody|3D structures of non-human antibody]]
-
<ref group="xtra">PMID:019074157</ref><references group="xtra"/>
+
== References ==
-
[[Category: Mus musculus]]
+
<references/>
-
[[Category: Boriack-Sjodin, P A.]]
+
__TOC__
-
[[Category: Clark, L A.]]
+
</StructureSection>
 +
[[Category: Large Structures]]
 +
[[Category: Lk3 transgenic mice]]
 +
[[Category: Boriack-Sjodin, P A]]
 +
[[Category: Clark, L A]]
[[Category: Antibody]]
[[Category: Antibody]]
[[Category: Domain swap]]
[[Category: Domain swap]]

Current revision

Crystal structure of LAC031, an engineered anti-VLA1 Fab

PDB ID 3eot

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools